Istradefylline is indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease (PD) experiencing "off" episodes.

The following clinically significant adverse reactions are: Dyskinesia Hallucinations / Psychotic Behavior Impulse Control / Compulsive Behaviors

Dyskinesia: Monitor patients for dyskinesia or exacerbation of existing dyskinesia.Hallucinations/Psychotic Behavior: Consider dosage reduction or stopping Istradefylline if occurs.Impulse Control/Compulsive Behaviors: Consider dosage reduction or stopping Istradefylline if occurs

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

Antiparkinson drugs

Istradefylline is a selective adenosine A2A receptor inhibitor. These receptors are found in the basal ganglia, a region of the brain that suffers degeneration in Parkinson's disease, and is also significantly involved in motor control. A2A receptors are also expressed on GABAergic medium spiny neurons within the indirect striato-pallidal pathway. The GABAergic action of this pathway is thereby reduced. Istradefylline has 56 times the affinity for A2A receptors than A1 receptors.

There are no adequate data on the developmental risk associated with the use of Istradefylline in pregnant women. There are no data on the presence of istradefylline in human milk, the effects of istradefylline on the breastfed infant, or the effects of istradefylline on milk production. Istradefylline was present in the milk of lactating rats at concentrations up to 10 times that in maternal plasma. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Istradefylline, and any potential adverse effects on the breastfed infant from Istradefylline or from the underlying maternal condition